Patient-Reported Outcomes from the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma

  1. Sangro, B.
  2. Galle, P.R.
  3. Kelley, R.K.
  4. Charoentum, C.
  5. De Toni, E.N.
  6. Ostapenko, Y.
  7. Heo, J.
  8. Cheng, A.-L.
  9. Wilson Woods, A.
  10. Gupta, C.
  11. Abraham, J.
  12. McCoy, C.L.
  13. Patel, N.
  14. Negro, A.
  15. Vogel, A.
  16. Abou-Alfa, G.K.
Aldizkaria:
Journal of Clinical Oncology

ISSN: 1527-7755,  0732-183X

Argitalpen urtea: 2024

Alea: 42

Zenbakia: 23

Orrialdeak: 2790-2799

Mota: Artikulua

DOI: 10.1200/JCO.23.01462 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus